The EGFR‐driven group (Group 1) exhibits a lack of T cell infiltration, especially CD8 T cell infiltration, which is consistent with the clinical observation that lung cancer patients with EGFR mutation tend to have an unfavorable response to PD‐1/PD‐L1 checkpoint inhibitors.24 The gene discussed is CD8A; the disease is lung carcinoma.